Superdisintegrants Market Report 2026

The superdisintegrants market size has grown strongly in recent years. It will grow from $1.16 billion in 2025 to $1.23 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to growth in solid oral dosage form production, increased use of crospovidone and sodium starch glycolate, expansion of generic pharmaceutical manufacturing, rising demand for fast-acting medications, advancements in tablet compression technologies.

The superdisintegrants market size is expected to see strong growth in the next few years. It will grow to $1.56 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to growing focus on patient-centric drug delivery, rising demand for pediatric and geriatric formulations, expansion of novel oral drug delivery systems, increasing R&D investment in excipient optimization, adoption of multifunctional excipient solutions. Major trends in the forecast period include increasing adoption of rapid disintegrating tablet formulations, rising demand for high-performance synthetic superdisintegrants, growing use of natural and plant-based disintegrants, expansion of orally disintegrating drug products, enhanced focus on bioavailability enhancement.

The growth in generic drug manufacturing is expected to drive the expansion of the superdisintegrants market in the coming years. Generic drugs are medicines that contain the same active ingredients, dosage form, strength, route of administration, quality, and performance as branded drugs but are generally offered at a lower cost. The rise in generic drug production is supported by increasing demand for cost-effective treatments, the expiration of patents for branded medicines, and government efforts to lower healthcare expenditures. In generic formulations, superdisintegrants play a critical role in improving tablet disintegration and dissolution, enabling faster drug release, enhanced bioavailability, and improved patient adherence. For example, in 2025, according to a report by the Association for Accessible Medicines, a US-based government organization, Americans filled about 3.9 billion prescriptions for generic drugs in 2024, compared to 435 million prescriptions for brand-name drugs, while total spending on generics reached only $98 billion. As a result, the rising production of generic drugs is fueling the growth of the superdisintegrants market.

Key players in the superdisintegrants market are emphasizing the development of innovative solutions, such as multifunctional disintegrants, to improve formulation efficiency, accelerate tablet disintegration, and enhance patient compliance in pharmaceutical applications. Multifunctional disintegrants are advanced excipients that integrate disintegration, binding, and flow-enhancing characteristics to optimize tablet manufacturing efficiency and drug release performance. For instance, in June 2023, Ashland Inc., a US-based chemicals company, introduced Polyplasdone Plus, a co-processed multifunctional direct-compression superdisintegrant developed to improve tablet disintegration, powder flow, and lubrication during pharmaceutical production. This advancement streamlines manufacturing by removing two processing steps, enhances tablet hardness, and supports high-speed as well as continuous manufacturing operations.

In April 2023, Ingredion Inc., a US-based food company, acquired Amishi Drugs & Chemicals Private Limited for an undisclosed value. Through this acquisition, Ingredion seeks to broaden its specialty pharmaceutical offerings, strengthen its capabilities in functional excipients, expand its footprint in the rapidly growing Indian pharmaceutical market, and support global exports with high-quality, pharmaceutical-grade ingredients. Amishi Drugs & Chemicals Private Limited is an India-based company that manufactures superdisintegrants to improve tablet disintegration and drug formulation performance.

Major companies operating in the superdisintegrants market are BASF SE, Merck KGaA, DuPont de Nemours Inc., IFF Pharma Solutions, Ingredion Incorporated, Roquette Freres SA., FMC Corporation, Azelis Group, Ashland Inc., Piramal Healthcare, Colorcon Inc. Ltd., Boai NKY Pharmaceuticals Ltd., JRS Pharma, Faran Shimi Pharmaceutical, DFE Pharma India Private Limited., Sigachi Industries Limited, Corel Pharma Chem, Maple Biotech Pvt. Ltd., Shanghai Chineway Pharmaceutical Technology Co. Ltd., JH Nanhang Life Sciences Co. Ltd.

North America was the largest region in the superdisintegrants market in 2025. The regions covered in the superdisintegrants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the superdisintegrants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the superdisintegrants market by increasing costs of imported polymers, cellulose derivatives, chemical processing agents, and specialized manufacturing equipment. Pharmaceutical excipient manufacturers in North America and Europe are most affected due to dependence on imported raw materials, while Asia-Pacific faces export-related cost pressures. These tariffs are raising formulation costs and affecting pricing strategies. At the same time, they are encouraging local production of excipient raw materials, regional manufacturing expansion, and innovation in cost-efficient superdisintegrant formulations.

The superdisintegrants market research report is one of a series of new reports that provides superdisintegrants market statistics, including superdisintegrants industry global market size, regional shares, competitors with a superdisintegrants market share, detailed superdisintegrants market segments, market trends and opportunities, and any further data you may need to thrive in the superdisintegrants industry. This superdisintegrants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Superdisintegrants are pharmaceutical excipients formulated to promote the rapid disintegration of tablets or capsules, enabling quicker release and absorption of the active pharmaceutical ingredient (API) in the body. They are essential for enhancing drug bioavailability and ensuring therapeutic effectiveness, particularly in orally administered medicines.

The main types of superdisintegrants include natural superdisintegrants, synthetic superdisintegrants, and other categories. Natural superdisintegrants are plant-based or naturally sourced substances that aid in the breakup of tablets within the gastrointestinal tract, thereby improving drug dissolution and absorption. Superdisintegrants are used in a variety of formulations, such as tablets and capsules, and are important across multiple therapeutic areas, including gastrointestinal disorders, neurological diseases, oncology, infectious diseases, cardiovascular diseases, and hematological diseases.

The superdisintegrants market consists of sales of co-processed superdisintegrants, polymer-based superdisintegrants, and cross-linked superdisintegrants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.